BSX Valuation Metrics
BSX Stock Price Metrics
BSX Dividend Metrics
BSX Growth Rate Metrics
BSX Discounted Cash Flow Metrics
| Fair Value Price | $111.42 |
| Margin of Safety | 137.47% |
BSX Revenue Metrics
BSX PE Ratio Metrics
| PE Ratio | 19.71 |
| PE Ratio Avg TTM | 48.98 |
| PE Ratio Avg 3Y | 69.01 |
| Current VS TTM Avg | -59.76% |
| Current VS 3Y Avg | -71.44% |
| Current VS 5Y Avg | -72.90% |
BSX PS Ratio Metrics
| PS Ratio | 3.40 |
| PS Ratio Avg TTM | 6.79 |
| PS Ratio Avg 3Y | 7.20 |
| Current VS TTM Avg | -49.95% |
| Current VS 3Y Avg | -52.78% |
| Current VS 5Y Avg | -47.17% |
BSX PB Ratio Metrics
| PB Ratio | 2.71 |
| PB Ratio Avg TTM | 5.55 |
| PB Ratio Avg 3Y | 5.55 |
| Current VS TTM Avg | -51.14% |
| Current VS 3Y Avg | -51.20% |
| Current VS 5Y Avg | -43.86% |
BSX Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 20.38 |
| PFCF Ratio Avg TTM | 37.92 |
| PFCF Ratio Avg 3Y | 54.12 |
| Current VS TTM Avg | -46.26% |
| Current VS 3Y Avg | -62.34% |
| Current VS 5Y Avg | -63.36% |
BSX Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.51 |
| Debt/Equity Ratio Avg TTM | 0.51 |
| Debt/Equity Ratio Avg 3Y | 0.51 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | -5.26% |
BSX PEG Ratio Metrics
| PEG Ratio | 0.88 |
| PEG Ratio Avg TTM | 2.57 |
| PEG Ratio Avg 3Y | 1.84 |
| Current VS TTM Avg | -65.83% |
| Current VS 3Y Avg | -52.17% |
| Current VS 5Y Avg | -69.63% |
BSX FCF Yield
| FCF Yield | 4.91% |
| FCF Yield Avg TTM | 2.85% |
| FCF Yield Avg 3Y | 1.79% |
| Current VS TTM Avg | +72.12% |
| Current VS 3Y Avg | +173.67% |
| Current VS 5Y Avg | +167.64% |
BSX Earnings Yield
| Earnings Yield | 5.07% |
| Earnings Yield Avg TTM | 2.22% |
| Earnings Yield Avg 3Y | 1.45% |
| Current VS TTM Avg | +128.59% |
| Current VS 3Y Avg | +249.66% |
| Current VS 5Y Avg | +273.15% |
BSX EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 19.21 |
| Ev/Ebit Ratio Avg TTM | 42.46 |
| Ev/Ebit Ratio Avg 3Y | 50.13 |
| Current VS TTM Avg | -54.75% |
| Current VS 3Y Avg | -61.68% |
| Current VS 5Y Avg | -58.45% |
BSX EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 14.07 |
| Ev/Ebitda Ratio Avg TTM | 28.68 |
| Ev/Ebitda Ratio Avg 3Y | 33.00 |
| Current VS TTM Avg | -50.95% |
| Current VS 3Y Avg | -57.36% |
| Current VS 5Y Avg | -54.63% |
BSX EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.80 |
| Ev/Assets Ratio Avg TTM | 3.31 |
| Ev/Assets Ratio Avg 3Y | 3.30 |
| Current VS TTM Avg | -45.60% |
| Current VS 3Y Avg | -45.42% |
| Current VS 5Y Avg | -37.25% |
BSX EV/Sales Ratio Metrics
| Ev/Sales Ratio | 3.86 |
| Ev/Sales Ratio Avg TTM | 7.35 |
| Ev/Sales Ratio Avg 3Y | 7.79 |
| Current VS TTM Avg | -47.48% |
| Current VS 3Y Avg | -50.44% |
| Current VS 5Y Avg | -45.33% |
BSX Current Ratio Metrics
| Current Ratio | 1.62 |
| Current Ratio Avg TTM | 1.35 |
| Current Ratio Avg 3Y | 1.38 |
| Current VS TTM Avg | +20.00% |
| Current VS 3Y Avg | +17.18% |
| Current VS 5Y Avg | +10.08% |
BSX Quick Ratio Metrics
| Quick Ratio | 1.08 |
| Quick Ratio Avg TTM | 0.86 |
| Quick Ratio Avg 3Y | 0.89 |
| Current VS TTM Avg | +25.58% |
| Current VS 3Y Avg | +21.35% |
| Current VS 5Y Avg | +6.06% |
BSX ROIC Metrics
| ROIC | 8.78% |
| ROIC Avg 3Y | 6.12% |
| ROIC Avg 5Y | 5.55% |
| Current VS 3Y Avg | +43.41% |
| Current VS 5Y Avg | +58.25% |
| Current VS 10Y Avg | +59.08% |
BSX Return on Assets Metrics
| ROA | 6.61 |
| ROA Avg TTM | 5.66 |
| ROA Avg 3Y | 4.50 |
| Current VS TTM Avg | +16.78% |
| Current VS 3Y Avg | +46.89% |
| Current VS 5Y Avg | +89.22% |
BSX Return on Equity Metrics
| ROE | 11.91 |
| ROE Avg TTM | 10.21 |
| ROE Avg 3Y | 8.16 |
| Current VS TTM Avg | +16.59% |
| Current VS 3Y Avg | +45.87% |
| Current VS 5Y Avg | +86.19% |
BSX Net Profit Margin Metrics
| Net Profit Margin | 14.38% |
| Net Profit Margin Avg TTM | 12.73% |
| Net Profit Margin Avg 3Y | 10.54% |
| Current VS TTM Avg | +13.01% |
| Current VS 3Y Avg | +36.50% |
| Current VS 5Y Avg | +72.35% |
Last Updated: Wednesday, June 17, 2026
About Boston Scientific Corporation
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael F. Mahoney